Pfizer (PFE) currently faces dual concerns in the market about its growth prospects and dividend safety, causing its valuation to remain low. However, from the perspective of financial ...

Key TakeawaysVaxcyte’s VAX-31 matched Pfizer’s Prevnar 20 on all 20 shared serotypes and Merck’s Capvaxive on 17 of 19 in a 4,047-person Phase 3 trial. Prevnar brought in $6.

Vaxcyte shares surged after its experimental VAX-31 pneumococcal vaccine met the main goals of a late-stage trial, though regulatory approval and commercial manufacturing remain years away.

Pfizer is a stock that looks well overdue for a rally. Although it's been rising this year, it can still have much more to ...

Moderna stock has surged nearly 600% this year on a cancer vaccine trial result that almost no one outside the trial has ...

A legal filing in Florida accuses pharmaceutical giant Pfizer Inc. PFE and Chairman and CEO Albert Bourla of deceiving ...

Vaxcyte is poised to capture significant share of a $3 billion to $6 billion market following the latest trial results, ...

Vaxcyte stock catapulted Monday after its experimental pneumococcal vaccine proved it's not inferior to marketed shots from ...

VAX-31 beat Pfizer and Merck’s established pneumococcal conjugate vaccines in a Phase 3 trial, exceeding investors’ most ...

Ten consecutive earnings beats and a shrinking COVID hangover have Wall Street split on whether Pfizer deserves a breakout or ...

Vaxcyte has seen its stock jump after the biotech’s 31-valent pneumococcal vaccine candidate went head-to-head with Pfizer’s Prevnar 20 and Merck & Co.’s Capvaxive in a phase 3 contest. The biotech ...